{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:56:41Z","timestamp":1791619001328,"version":"4.3.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.critrevonc.2014.10.006","type":"journal-article","created":{"date-parts":[[2014,10,12]],"date-time":"2014-10-12T16:32:28Z","timestamp":1413131548000},"page":"203-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":144,"title":["A review of relative dose intensity and survival in patients with metastatic solid tumors"],"prefix":"10.1016","volume":"93","author":[{"given":"Laura J.","family":"Havrilesky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Reiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuong Khanh","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2014.10.006_bib0005","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/cncr.22939","article-title":"Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy","volume":"110","author":"Shayne","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2014.10.006_bib0010","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1177\/107327480301000507","article-title":"Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate-grade non-Hodgkin's lymphoma","volume":"10","author":"Chrischilles","year":"2003","journal-title":"Cancer Control"},{"key":"10.1016\/j.critrevonc.2014.10.006_bib0015","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10549-008-0018-1","article-title":"Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients","volume":"114","author":"Chirivella","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.critrevonc.2014.10.006_bib0020","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/oxfordjournals.annonc.a058727","article-title":"P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL)","volume":"5","author":"Bertini","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2014.10.006_bib0025","first-page":"533","article-title":"Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma","volume":"24","author":"Epelbaum","year":"1988","journal-title":"Isr J Med Sci"},{"key":"10.1016\/j.critrevonc.2014.10.006_bib0030","series-title":"Adjuvant therapy of cancer V","first-page":"13","article-title":"The effect of dose intensity in adjuvant chemotherapy","author":"Hryniuk","year":"1987"},{"key":"10.1016\/j.critrevonc.2014.10.006_bib0035","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1200\/JCO.1990.8.6.963","article-title":"Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis","volume":"8","author":"Kwak","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2014.10.006_bib0040","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/oxfordjournals.annonc.a058619","article-title":"Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d\u2019Etude des Lymphomes de l\u2019Adulte)","volume":"4","author":"Lepage","year":"1993","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2014.10.006_bib0045","first-page":"107","article-title":"Dose intensity of cisplatin-based chemotherapy in epithelial ovarian carcinoma. An important factor affecting survival","volume":"16","author":"Nemet","year":"1995","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.critrevonc.2014.10.006_bib0050","first-page":"2027","article-title":"The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity","volume":"4","author":"Frei","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2014.10.006_bib0055","first-page":"121","article-title":"The importance of dose intensity in the outcome of chemotherapy","author":"Hryniuk","year":"1996","journal-title":"Important Adv Oncol"},{"key":"10.1016\/j.critrevonc.2014.10.006_bib0060","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00277-007-0399-y","article-title":"Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP","volume":"87","author":"Bosly","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.critrevonc.2014.10.006_bib0065","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1097\/JTO.0b013e3181eba7f9","article-title":"Modest reductions in dose intensity and drug-induced neutropenia have no major impact on survival of patients with non-small cell lung cancer treated with platinum-doublet chemotherapy","volume":"5","author":"Brunetto","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.critrevonc.2014.10.006_bib0070","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.lungcan.2008.01.010","article-title":"Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale)","volume":"61","author":"Gebbia","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2014.10.006_bib0075","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3892\/etm.2012.597","article-title":"Comparison of docetaxel\/cisplatin dosages of 75\/60 and 60\/60mg\/m(2) for the treatment of non-small cell lung cancer","volume":"4","author":"Kim","year":"2012","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.critrevonc.2014.10.006_bib0080","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.cllc.2012.11.005","article-title":"Paclitaxel-loaded polymeric micelle (230mg\/m(2)) and cisplatin (60mg\/m(2)) vs. paclitaxel (175mg\/m(2)) and cisplatin (60mg\/m(2)) in advanced non-small-cell lung cancer: a multicenter randomized phase IIB trial","volume":"14","author":"Lee","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.critrevonc.2014.10.006_bib0085","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/jnci\/djn088","article-title":"A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial","volume":"100","author":"Leyvraz","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.critrevonc.2014.10.006_bib0090","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.lungcan.2008.12.019","article-title":"Dose intensity correlate with survival in elderly patients treated with chemotherapy for advanced non-small cell lung cancer","volume":"66","author":"Luciani","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2014.10.006_bib0095","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1177\/030089161109700406","article-title":"Doses of capecitabine and oral vinorelbine are not relevant for efficacy in breast cancer patients: an analysis of dose intensity","volume":"97","author":"Battelli","year":"2011","journal-title":"Tumori"},{"key":"10.1016\/j.critrevonc.2014.10.006_bib0100","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1471-2407-11-131","article-title":"Evaluating the impact of relative total dose intensity (RTDI) on patients\u2019 short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer\u2014a pooled analysis","volume":"11","author":"Loibl","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2014.10.006_bib0105","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/jnci\/djq530","article-title":"Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer","volume":"103","author":"Fruscio","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.critrevonc.2014.10.006_bib0110","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ygyno.2012.12.017","article-title":"Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer","volume":"129","author":"Hanna","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2014.10.006_bib0115","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1006\/gyno.2000.5923","article-title":"High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC)","volume":"78","author":"Joly","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.critrevonc.2014.10.006_bib0120","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1080\/028418602320404998","article-title":"Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum","volume":"41","author":"Rosenberg","year":"2002","journal-title":"Acta Oncol"}],"updated-by":[{"DOI":"10.1016\/j.critrevonc.2026.105163","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000}},{"DOI":"10.1016\/j.critrevonc.2026.105163","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000}}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842814001577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842814001577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:16:35Z","timestamp":1777605395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842814001577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S1040842814001577"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2014.10.006","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review of relative dose intensity and survival in patients with metastatic solid tumors","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2014.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}